Next Article in Journal
Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
Previous Article in Journal
Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2014, 82(4), 815-824; doi:10.3797/scipharm.1406-16

Efficacy and Safety of Dorocontin® versus Sustac® in the Treatment of Stable Angina Pectoris: A Randomized, Double-Blind Comparative Trial

1
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2
Cardiovascular Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3
Department of Cardiology, Baqiyatallah University of Medical Sciences, Tehran, Iran
4
Neurogenic Inflammation Research Center, Department of Modern Sciences and Technologies, Mashhad University of Medical Sciences, Mashhad, Iran
5
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
6
Cardiometabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
*
Authors to whom correspondence should be addressed.
Received: 30 June 2014 / Accepted: 16 August 2014 / Published: 16 August 2014
Download PDF [113 KB, uploaded 28 September 2016]

Abstract

Background: Development of generic drugs has numerous benefits in terms of cost-efficiency and availability. Slow-release nitroglycerin is a vasodilator drug commonly prescribed for patients with angina pectoris. Objective: The objective of this study was to compare the efficacy and safety of generic slow-release nitroglycerin (Dorocontin®) with that of the innovator brand (Sustac®) in patients with stable angina pectoris. Methods: In this randomized, double-blind comparative trial, 110 patients were allocated to Dorocontin® (n=67) or Sustac® (n=43) at a dose of 6.4 mg TID, for a total period of two months. Maximum endurable MET (metabolic equivalent of task), MPI (myocardial perfusion imaging), along with changes in the ECG and biomarkers of renal (serum creatinine, BUN) and hepatic (AST, ALT, and ALP) function, lipid profile (total cholesterol, LDL-C, HDL-C, VLDL-C, and triglycerides), electrolytes (Na+ and K+), CBC-diff (RBC, WBC, Plt, Hb, Hct, MCV, MCH, MCHC, and RDW), and FBS were assessed at the baseline and at the end of the trial. The frequency of adverse events during the course of the trial was also recorded. Results: Apart from a significantly greater reduction in maximum ST depression in the Sustac® versus the Dorocontin® group (p=0.03), none of the functional (MET, MPI, and ECG) and paraclinical (renal function, hepatic function, lipid profile, electrolytes, and FBS) parameters significantly differed between the study groups. The mean Hb (p=0.035), Hct (p=0.045), and MCH (p=0.032) were decreased by the end of the trial in the Sustac®, but not in the Dorocontin® group, whilst there was no change in other CBC-diff parameters. Reported adverse events were not serious and included headache, vertigo, gastrointestinal upset, and orthostatic hypotension. The frequency of these adverse events was comparable between the study groups. Conclusion: The findings of the present trial showed comparable efficacy and safety of the generic and innovator products of slow-release nitroglycerin in the management of stable angina pectoris.
Keywords: Angina Pectoris; Nitrate; Glyceryl trinitrate; Generic; Randomized controlled trial Angina Pectoris; Nitrate; Glyceryl trinitrate; Generic; Randomized controlled trial
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

PANAHI, Y.; PISHGOO, B.; DADJOU, Y.; MEHDIRAD, M.; SOFLAEI, S.S.; SAHEBKAR, A. Efficacy and Safety of Dorocontin® versus Sustac® in the Treatment of Stable Angina Pectoris: A Randomized, Double-Blind Comparative Trial. Sci. Pharm. 2014, 82, 815-824.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top